During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the world’s tallest mountains, and experiencing…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the world’s tallest mountains, and experiencing…
MYELOMA
Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time until disease progression in patients with smoldering multiple myeloma who were not yet experiencing any symptoms of…
MYELOMA
Adding Darzalex (daratumumab) to the standard pre-transplant therapy for multiple myeloma significantly increased the number of patients showing no signs of cancer after…
STRO-001, Sutro Biopharma’s investigational therapy for multiple myeloma, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). “There…
The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its investigational therapy selinexor as…
MYELOMA
Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from England’s National Cancer Patient Experience…
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.